David Jones, MD
Cardiovascular Disease · Little Rock, ARNPI 1790855534
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.7% of the total across 217 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 24 manufacturers reported payments, led by Novartis at 25.5% of the total. Reporting peaked in 2019 at $839 and has fallen 74.4% since, to $215 in 2025. That places this record below the midpoint for cardiovascular disease clinicians in AR, where the typical reported total is $3,368.
Across 217 payments — averaging $15.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$845
- E.r. Squibb & Sons, L.L.C.$390
- Boston Scientific$385
- Johnson & Johnson$375
- Abbott$293
- Amgen$198
- plus $823 from 18 others
Across 37 payments — averaging $12,693 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$299K
- Boehringer Ingelheim Pharma GmbH & Co.kg$62K
- Novartis$59K
- Boehringer Ingelheim International GmbH$39K
- Alnylam Pharmaceuticals Inc.$6K
- AstraZeneca$4K
What the payments were for
- Food & beverage$3,299100%
- Education$100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 75 | $845 |
| E.r. Squibb & Sons, L.L.C. | 35 | $390 |
| Boston Scientific | 22 | $385 |
| Johnson & Johnson | 26 | $375 |
| Abbott | 9 | $293 |
| Amgen | 11 | $198 |
| Heartflow, Inc. | 2 | $158 |
| Abiomed | 1 | $103 |
| Pfizer | 7 | $97 |
| AstraZeneca(2 entities) | 6 | $79 |
| Sanofi-aventis U.S. LLC | 5 | $69 |
| Baxter Healthcare | 3 | $67 |
| Philips North America LLC | 3 | $44 |
| Irhythm Technologies, Inc. | 2 | $36 |
| Shockwave Medical, Inc | 1 | $24 |
| Cvrx, Inc. | 1 | $21 |
| Atricure, Inc. | 1 | $18 |
| Lundbeck LLC | 1 | $18 |
| Cardiva Medical, Inc. | 1 | $17 |
| Bridgebio Pharma, Inc. | 1 | $17 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $16 |
| Merck | 1 | $15 |
| Amarin Pharma, Inc. | 1 | $12 |
| Boehringer Ingelheim | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FFRct$133
- CARDIOMEMS$115
- Impella$103
How this compares
$3,308 in reported general payments places this provider in the 45th percentile of 130 cardiovascular disease providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 1,843 | $1,364,155 |
| EntrestoSacubitril/Valsartan | 498 | $361,395 |
| XareltoRivaroxaban | 330 | $239,899 |
| Repatha SureclickEvolocumab | 287 | $201,176 |
| MultaqDronedarone Hcl | 63 | $56,793 |
| Praluent PenAlirocumab | 75 | $39,254 |
| NexletolBempedoic Acid | 83 | $38,345 |
| JardianceEmpagliflozin | 19 | $17,259 |
| Atorvastatin Calcium | 1,744 | $15,258 |
| BrilintaTicagrelor | 28 | $14,633 |
| Rosuvastatin Calcium | 1,081 | $12,055 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 71 | $10,513 |
| Ranolazine ErRanolazine | 151 | $9,826 |
| Propafenone Hcl | 137 | $9,604 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 633 | $8,936 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $97 | $1,364,1551,843 claims |
| NovartisEntresto | $845 | $361,395498 claims |
| Johnson & JohnsonXarelto | $375 | $239,899330 claims |
| Sanofi-aventis U.S. LLCMultaq | $69 | $56,79363 claims |
| Boehringer IngelheimJardiance | $12 | $17,25919 claims |
| AstraZenecaBrilinta | $79 | $14,63328 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 130 cardiovascular disease providers in Arkansas.
Other cardiovascular disease in Little Rock
- Ian CawichLittle Rock$294K
- William RollefsonLittle Rock$74K
- Andre PaixaoLittle Rock$73K
- Wesley LaneLittle Rock$46K
- Omar QaqishLittle Rock$45K
- Barry UretskyLittle Rock$36K
- Freddy ChrismanLittle Rock$26K
- Forrest GloverLittle Rock$17K
- Clayton BorgLittle Rock$14K
- David MegoLittle Rock$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.